HolmesC.J.Biocompatibility of peritoneal dialysis solutions.Perit Dial Int1993; 13: 88–94.
2.
De FijterC.W.H., OeP.L., DonkerA.J.M., VerhoefJ., VerbrughH.A.Compatibility of peritoneal dialysis fluids containing alternative osmotic agents with cells present in the peritoneal cavity.Perit Dial Int1994; 14(Suppl 2): S33–8.
BreborowiczA., MartisL., OreopoulosD.G.In vitro influence of lactate on function of peritoneal fibroblasts. In: KhannaR., ed. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Publications, 1994; 10: 225–9.
5.
WieslanderA.P., NordinM.K., MartinsonE., KjellstrandP.T.T., BoberV.C.Heat sterilized PD fluids impair growth and inflammatory responses of cultured cell lines and human leukocytes.Clin Nephrol1993; 39: 343–8.
6.
De FijterC.W.H., VerbrughH.A., PetersE.D.J.In vivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD.Clin Nephrol1993; 39: 75–80.
7.
DuweA.K., VasS.I., WeatherheadJ.W.Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocystosis and bactericidal activity in vitro.Infect Immun1981; 33: 130–5.
8.
AlobaidiH.M., ColesG.A., DaviesM., LloydD.Host defence in continuous ambulatory peritoneal dialysis; the effect of the dialysate on phagocyte functionNephrol Dial Transplant1986; 1: 16–21.
van BronswijkH., VerbrughH.A., BosH.J.Cytotoxic effects of commercial continuous ambulatory peritoneal dialysis (CAPD) fluids and of bacterial exoproducts on human mesothelial cells in vitro.Perit Dial Int1989; 9: 197–202.
11.
BreborowiczA., RodelaH., OreopoulosD.G.Toxicity of osmotic solutes on human mesothelial cells in vitro.Kidney Int1992; 41: 1280–5.
12.
BreborowiczA., BalaskasE., OreopoulosG.D., MartisL., SerkesK., OreopoulosD.G.In vitro study of the effect of osmotic solutes on the interactions between cells from the peritoneum and peritoneal cavity.Perit Dial Int1994; 14: 149–54.
13.
RubinJ., HerreraG.A., CollinsD.An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis.Am J Kidney Dis1991; 18: 97–102.
14.
DobbieJ.W.Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis.Perit Diallnt1992; 12: 14–27.
15.
YamadaK., MiyaharaY., HamaguchiK.Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure.Clin Nephrol1994; 42: 354–61.
16.
LameireN.H., VanholderR., VeytD., LambertM-C, RingoirS.A longitudinal, five year survey of urea kinetic parameters in CAPD patients.Kidney Int1992; 42: 426–32.
17.
HeimbürgerO., WaniewskiJ., WerynskiA., TranaeusA., LindholmB.Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity.Kidney Int1990; 38: 495–506.
MistryC.D., GokalR., PeersE, and MIDAS Study Group. A randomised multicentre clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutes in CAPD.Kidney Int1994; 46: 496–503.
